Illumina and CENTOGENE
Using NIPT to Screen for the Most Common Fetal Chromosomal Abnormalities
July 24, 2017
3 p.m. CEST
Using NIPT To Screen for the Most Common Fetal Chromosomal Abnormalities
Illumina VeriSeq™ NIPT Solution*
CENTOGENE has a new addition to its prenatal portfolio: CentoNIPT®, its innovative non-invasive prenatal testing that provides a fast and accurate screening for the most common prenatal chromosomal abnormalities (Trisomy 21, Trisomy 18, Trisomy 13 and sex chromosomes).
CentoNIPT® combines next generation sequencing with integrated measurement of fetal fraction, even when the fetal fraction is less than 4%. Based on the Illumina Verifi Prenatal Test & VeriSeq™ NIPT solution, CentoNIPT® promises the lowest test failure rate among NIPT technologies on market (30 – 50 % lower).
- Introduction to NIPT and difference with classic prenatal testing
- Pre-test and post-test counseling considerations
- Report example – CENTOGENE base
Notation: *Sample Preparation and analysis software are CE-IVD marked.
Genetic Counselor at Illumina
Kristin Dalton, a licensed and certified Genetic Counselor, joined Illumina's […]
Prof. Peter Bauer, M.D.
Chief Genomic Officer, CENTOGENE
Prof. Peter Bauer, M.D., serves as CENTOGENE’s Chief Genomic Officer, where he combines […]
Watch Our CentoTalks on demand
Our interactive webinars that feature key developments in clinical diagnostics.